louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT01610128: Development of an Urticaria Control Test
Official title: UCT - Development of an Instrument to Assess Disease Control in Patients With Chronic Urticaria (Urticaria Control Test)
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Chronic Urticaria
Keywords: urticaria, patient reported outcome
Lead sponsor: Charite University, Berlin, Germany
Sponsor class: OTHER
First posted: 2012-06-01
Enrollment: 508
Sex: ALL
Minimum age (years): 12
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: all patients suffering from chronic forms of urticaria

Brief summary: The aim of the project is to develop a patient reported outcome instrument to assess disease control in chronic urticaria patients (Urticaria Control Test - UCT) of age 12 and older.


Eligibility criteria: Inclusion Criteria:

all patients suffering from chronic forms of urticaria are eligible

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Mainz
country: Germany
facility: Universitätshautklinik Mainz
state: Rheinland-Pfalz
city: Berlin
country: Germany
facility: Allergie-Centrum-Charite
Study officials:
References:
Clinical trial NCT04130828: Thrice-weekly Versus Thrice-daily Oral Ferrous Fumarate Treatment in Adult Patients With Iron Deficiency Anemia
Official title: Thrice-weekly Versus Thrice-daily Oral Ferrous Fumarate Treatment in Adult Patients With Iron Deficiency Anemia
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Iron Deficiency Anemia
Keywords: ferrous fumarate
oral iron treatment
thrice-weekly
thrice-daily
iron deficiency anemia
Lead sponsor: Prince of Songkla University
Sponsor class: OTHER
Collaborators: name: The Thai Society of Hematology
First posted: 2019-10-17
Enrollment: 66
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Iron deficiency anemia is a global health problem and the most common cause of anemia worldwide. Patients with iron deficiency and Iron deficiency anemia can present with a multitude of symptoms including fatigue, dyspnea on exertion, dysphagia, pallor, palpitations, headaches, tinnitus, taste disturbance and pica. Oral iron supplementation is associated with increasing hemoglobin in multiple studies in women, pregnant women and elderly patients. However, the optimal dose and frequency of oral iron supplementation for treatment remains unclear. The current proposed study attempts to address this gap in the literature.


Eligibility criteria: Inclusion Criteria:

* Age \>18 years
* Patients with iron deficiency anemia defined as hemoglobin less than 12 g/dL in women or 13 g/dL in men; AND ferritin less than 30 ng/mL

Exclusion Criteria:

* Allergy to iron
* Currently pregnancy
* Currently breastfeeding
* Known history of inflammatory bowel disease, celiac disease, inherited bleeding disorder, solid cancer, hematologic cancer or thalassemia
* Renal impairment or glomerular filtration rate less than 30 ml/min/1.73m2
* Hepatic impairment or Child Pugh score more than 7
* Active bleeding define hemoglobin decrease more than 2 g/dL
* Multivitamin and mineral supplement (35 mg or more of elemental iron per day) in 2 weeks prior to randomization
* Non-literate

Subject withdrawal criteria:

* Intolerance to drugs
* Active bleeding define hemoglobin decrease more than 2 g/dL
* Major surgery
* Blood transfusion
* Loss follow-up more than 2 weeks

Primary outcomes:
measure: Proportion of patient who achieved hemoglobin target
timeFrame: 12 weeks
Secondary outcomes:
measure: Safety and Tolerability: Incidence of Treatment-Emergent Adverse Events
timeFrame: 12 weeks
Other outcomes:
Locations:
city: Hat Yai
country: Thailand
facility: Songklanagarind Hospital
state: Songkhla
Study officials:
References:
Clinical trial NCT01638728: Change of Depth in a RAE Tube: Tube Fixation at the Midline or Angle and in a Neutral or Neck Extended Position
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Depth of Tracheal Tube
Lead sponsor: Kyung Hee University Hospital at Gangdong
Sponsor class: OTHER
First posted: 2012-07-12
Enrollment: 100
Sex: ALL
Minimum age (years): 18
Maximum age (years): 90
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_CROSSOVER
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: adult patients who are scheduled for elective surgery under general anesthesia

Brief summary: The investigators compared the depth of the RAE tube \[Preformed oral tracheal tubes were first described by Ring, Adair and Elwyn (therefore called RAE tubes)\] when fixed at the midline and at the angle of the mouth, and after fixing the tube at the angle.


Eligibility criteria: Inclusion Criteria:

* Patients who are scheduled for elective surgery under general anesthesia

Exclusion Criteria:

* Patients with anatomical defects of the face, neck, or upper airway

Primary outcomes:
measure: depth of tube
timeFrame: up to 1 hour
Secondary outcomes:
Other outcomes:
Locations:
city: Seoul
country: Korea, Republic of
facility: Kyung Hee University Hospital at Gangdong
Study officials:
References:
Clinical trial NCT01491828: Study to Determine Results of Vibratory Stimulus on Subject's Neck
Official title: Study to Determine Results of Vibratory Stimulus on Subject's Neck
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Sleep Apnea
Snoring
Keywords: Apnea
Sleep apnea
Snoring
Hypoglossal nerve stimulation
Laynx stimulation
Lead sponsor: Kai Medical, Inc.
Sponsor class: INDUSTRY
First posted: 2011-12-14
Enrollment: 100
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NA
Intervention model: SINGLE_GROUP

Brief summary: This study will validate whether an external vibratory stimulus applied to a subject's neck causes head, neck or jaw movement.

Detailed description: This study will validate whether an external vibratory stimulus applied to a subject's neck causes head, neck or jaw movement, and provide information regarding the optimum location and variable vibration parameters of vibratory stimulus on a subject's neck to cause head, neck, or jaw movement. The study will also provide information whether the subject experienced or did not experience a change in sleep stage or arousal by vibratory stimulus on a subject's neck. The data gathered from this study will be used for future studies in analyzing whether such vibratory stimulus can serve as a potential treatment for sleep disorders, such as snoring and obstructive sleep apnea.

Eligibility criteria: Inclusion Criteria:

* Male or female, ages 18 to 80 years old
* Able to provide written informed consent for themselves and comply with study procedures.

Exclusion Criteria:

* Known hyposensitivity or hypersensitivity to vibrations on neck.
* Neurological disorder such as seizure disorder or narcolepsy.
* Psychiatric disorders currently not under control.
* Insomniacs.
* Pregnant women.

Primary outcomes:
measure: Head, neck, or jaw movement
timeFrame: 1 month
Secondary outcomes:
measure: Affect of sleep stage
timeFrame: 1 month
Other outcomes:
Locations:
city: Honolulu
country: United States
facility: Kai Medical Sleep Lab
state: Hawaii
Study officials:
name: Kelley Ford Shippey III, MD, MS
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01994928: Preoxygenation in the Intensive Care Unit Using a Nose-mouth Mask Versus High-flow Nasal Cannula Oxygen.
Official title: Prospective Randomised Study on Preoxygenation in the Intensive Care Unit Using a Nose-mouth Mask Versus High Flow Nasal Cannula Oxygen.
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Respiratory Failure
Lead sponsor: Universitätsklinikum Hamburg-Eppendorf
Sponsor class: OTHER
First posted: 2013-11-26
Enrollment: 40
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Preoxygenation is routinely performed before endotracheal intubation. In the intensive care unit, preoxygenation is often accomplished using a nose-mouth mask. It seems probable that high flow nasal cannula oxygen, which is used in the treatment of patients with hypoxemic respiratory failure, is equally effective in preventing the development of hypoxemia during intubation. In this prospective randomized study preoxygenation using high flow nasal cannula oxygen is compared with preoxygenation via nose-mouth mask in patients with hypoxemic respiratory failure.


Eligibility criteria: Inclusion Criteria:

* patients treated in an intensive care unit
* indication for intubation
* presence of hypoxemic (SaO2/fraction of inspired oxygen(FiO2): 300 or less) respiratory failure
* informed consent

Exclusion Criteria:

* blocked nasopharynx
* contraindications for nose-mouth mask or high flow nasal cannula oxygen
* expected difficult airway

Primary outcomes:
measure: Mean decrease in the saturation of oxygen (SpO2) during intubation.
timeFrame: during intubation
Secondary outcomes:
measure: Changes in blood gases after intubation.
timeFrame: 30 minutes after intubation
Other outcomes:
measure: Changes in hemodynamics.
timeFrame: during intubation and up to 30 minutes after intubation
Locations:
city: Hamburg
country: Germany
facility: Universitätsklinikum Hamburg-Eppendorf, Department of Intensive Care Medicine
Study officials:
References:
citation: Simon M, Wachs C, Braune S, de Heer G, Frings D, Kluge S. High-Flow Nasal Cannula Versus Bag-Valve-Mask for Preoxygenation Before Intubation in Subjects With Hypoxemic Respiratory Failure. Respir Care. 2016 Sep;61(9):1160-7. doi: 10.4187/respcare.04413. Epub 2016 Jun 7.
Clinical trial NCT00629928: Ulcer Prevention II
Official title: A Comparative Efficacy and Safety of Nexium Delayed-Release Capsules (40mg qd and 20mg qd) Versus Placebo for the Prevention of Gastric and Duodenal Ulcers Associated With Daily NSAID Use in Patients at Risk
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: NSAID Associated Gastric Ulcers
Keywords: NSAID, Nexium, esomeprazole, Gastric Ulcers
Lead sponsor: AstraZeneca
Sponsor class: INDUSTRY
First posted: 2008-03-06
Enrollment: 800
Sex: ALL
Minimum age (years): 18
Maximum age (years): 60
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: Nonsteroidal anti-inflammatory drugs (NSAIDS) are often associated with gastric ulcers. This study looks at the prevention of these gastric ulcers, in patients deemed to be at risk, with either esomeprazole 40 mg once daily; esomeprazole 20 mg once daily.


Eligibility criteria: Inclusion Criteria:

1. No active/current gastric or duodenal ulcer on baseline endoscopy.
2. A clinical diagnosis of a chronic condition that requires daily NSAID treatment for at least 6 months.
3. Other inclusion criteria, as defined in the protocol.

Exclusion Criteria:

1. History of esophageal, gastric or duodenal surgery, except the simple closure of an ulcer.

* 2. History of severe liver disease, including (but not limited to) cirrhosis and acute or chronic hepatitis.
* 3. Other criteria, as defined in the protocol.

Primary outcomes:
measure: To assess the efficacy of esomeprazole 40 mg qd versus placebo and esomeprazole 20 mg qd versus placebo for up to 6 months of treatment for the prevention of gastric (and duodenal) ulcers in patients receiving daily NSAID therapy.
timeFrame: Assessments at Week 0, Week 4, Week 12, Week 26
Secondary outcomes:
measure: Investigator assessed symptoms, defined as control of NSAID-associated GI symptoms for up to 6 months of treatment with esomeprazole 40 mg qd versus placebo and esomeprazole 20 mg qd versus placebo in patients receiving daily NSAID therapy.
timeFrame: Assessments at Week 0, Week 4, Week 12, Week 26
measure: Safety and tolerability of esomeprazole 40 mg qd versus placebo and esomeprazole 20 mg qd versus placebo when administered for up to 6 months to patients receiving daily NSAID therapy.
timeFrame: Assessments at Week 0, Week 4, Week 12, Week 26
Other outcomes:
Locations:
Study officials:
affiliation: Nexium Global Product Director, AstraZeneca
name: Paula Fernstrom
role: STUDY_DIRECTOR
References:
Clinical trial NCT05526261: Benign Thyroid Nodules / Benign Goiter. What Subjective Problems Are Improved With an Operation and Can This be Predicted Preoperatively?
Official title: Benign Thyroid Nodules / Benign Goiter. What Subjective Problems Are Improved With an Operation and Can This be Predicted Preoperatively?
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Thyroid Nodule
Lead sponsor: Linkoeping University
Sponsor class: OTHER_GOV
First posted: 2022-09-02
Enrollment: 150
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Patientens with compression symptoms in the neck

Brief summary: Nodules in the thyroid gland are common. Patients discover these lumps either because of their visible size increase or because of local discomforts such as difficulty swallowing, difficulty breathing or voice changes. The thyroid gland is in close connection with the esophagus, trachea and the vocal nerve. Thus, a lump in the thyroid gland can cause pressure symptoms from these organs. In the event of such complaints, patients are referred for investigation. If it turns out that the patient has a lump in the thyroid gland ("goiter"), further investigation is carried out with an ultrasound examination and sampling with a needle from the lump (puncture).

At present, most thyroid nodules are examined cytologically, ie the thyroid nodules are punctured with a thin needle and the cells that are obtained are analyzed by a cytologist. The material is graded according to Bethesda classification. Higher grading is associated with a higher risk that the tuber is malignant. Lower grading is associated with a lower probability that the tuber can be malignant. If these patients are operated on, it is usually with the hope that their local ailments improve.

We want to investigate which patients who have a lump in the thyroid gland and experience pressure problems experience an improvement after a thyroid operation.


Eligibility criteria: Inclusion Criteria:

* Patients with a thyroid nodule who have local problems and where surgery (hemithyroidectomy) is planned
* 18 years or older
* Bethesda I-IV

Exclusion Criteria:

-

Primary outcomes:
measure: Symptom improvement
timeFrame: One year follow upp
Secondary outcomes:
measure: Comparision of questionnaries
timeFrame: 2024
Other outcomes:
Locations:
city: Linköping
country: Sweden
facility: Linköpings University
state: Östergötland
Study officials:
affiliation: Professor Oliver Gimm
name: Oliver Gimm, Professor
role: STUDY_DIRECTOR
References:
Clinical trial NCT04312061: Effect of Oral Tramadol Administration Prior to IUD Insertion
Official title: Safety and Efficacy of Oral Tramadol Administration in Reducing Pain During Levonorgestrel Intrauterine Device Insertion in Adolescents and Young Women: a Randomized Controlled Trial
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE3
Conditions: Contraception
Lead sponsor: Cairo University
Sponsor class: OTHER
First posted: 2020-03-18
Enrollment: 108
Sex: FEMALE
Minimum age (years): 14
Maximum age (years): 25
Standard ages: CHILD
ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: the aim of the study is to evaluate the safety and efficacy of oral tramadol administration in reducing pain during LNG- IUD insertion in adolescents and young women


Eligibility criteria: Inclusion Criteria:

* nulliparous adolescents and young women requesting LNG-IUD insertion

Exclusion Criteria:

* parous women, contraindications to LNG-IUD insertion and allergy or contraindications to tramadol

Primary outcomes:
measure: pain during IUD insertion
timeFrame: 5 minutes
Secondary outcomes:
measure: duration of the procedure
timeFrame: 5 minutes
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT06345261: Diphenhydramine in Catheter Related Bladder Discomfort
Official title: Role of Diphenhydramine in Prevention of Catheter Related Bladder Discomfort
Study type: INTERVENTIONAL
Overall status: ENROLLING_BY_INVITATION
Phase: NA
Conditions: Catheter Complications
Lead sponsor: Cairo University
Sponsor class: OTHER
First posted: 2024-04-03
Enrollment: 104
Sex: MALE
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: Diphenhydramine has H1-antihistamine action, it also possesses anti-muscarinic properties. Thus, diphenhydramine might be able to reduce the problem of catheter related bladder discomfort by inhibiting smooth muscle spasm of the urinary bladder via its anti-muscarinic action .


Eligibility criteria: Inclusion Criteria:

male patients aged more than18-80 years ASA I and II , upper ureteric stone removal under general anesthesia r

Exclusion Criteria:

overactive bladder cognitive impairment a neuropsychological disorder, bladder outflow obstruction urinary tract infection, , neurogenic bladder, operative time \> 6 h

Primary outcomes:
measure: incidence of catheter related bladder discomfort postoperative
timeFrame: UP TO 6 HOURE
Secondary outcomes:
measure: visual analog scale (VAS)
timeFrame: up to 6 hours
Other outcomes:
Locations:
city: Cairo
country: Egypt
facility: Cairo university
Study officials:
affiliation: Cairo university , Cairo, Egypt
name: Amr s wahdan, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06988761: The Clinical Impact of Integrated Behavioral Health Techniques in Patients With Fibromyalgia
Official title: The Clinical Impact of Integrated Behavioral Health Techniques in Patients With Fibromyalgia: A Mayo Clinic-Lin Health Randomized Controlled Trial
Study type: INTERVENTIONAL
Overall status: NOT_YET_RECRUITING
Phase: NA
Conditions: Fibromyalgia
Lead sponsor: Mayo Clinic
Sponsor class: OTHER
First posted: 2025-05-25
Enrollment: 300
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this research is to assess the impact of using Lin Health to provide virtual long-term follow up care for patients with a diagnosis of fibromyalgia.


Eligibility criteria: Inclusion Criteria:

* Patient must be 18 years of age or older.
* Patient must have a diagnosis of Fibromyalgia.
* Patient must be being seen at the Mayo Clinic Fibromyalgia and Chronic Fatigue Clinic in Rochester, MN.
* Patient must be able to understand and provide informed consent and HIPAA authorization
* Patient must be willing and able to complete all aspects of the study.
* Patient must be able to speak and read English.

Exclusion Criteria:

* Patient who is under the age of 18 years old.
* Patient who is unable to provide informed consent or HIPAA authorization.
* Patient who declines study participation.
* Patient who is unable to speak English.
* Patient who is on active cancer therapy.
* Patient who is actively psychotic or actively suicidal.
* Patient who is deemed inappropriate to the study by the medical professional.

Primary outcomes:
measure: Fibromyalgia Impact Questionnaire - Revised
timeFrame: Baseline, 3 months
Secondary outcomes:
Other outcomes:
Locations:
city: Rochester
country: United States
facility: Mayo Clinic
state: Minnesota
Study officials:
affiliation: Mayo Clinic
name: Elizabeth C. Wight, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00175461: Comparison of Two Minimally Invasive Surgical Techniques for Hip Replacement
Official title: Comparison of the Clinical Effectiveness and Cost-effectiveness of the MIS Anterolateral Approach (MIS Watson Jones, G3) Versus Anterolateral Mini or Posterolateral Mini Approaches in Primary Total Hip Arthroplasty
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Osteoarthritis
Lead sponsor: University of British Columbia
Sponsor class: OTHER
First posted: 2005-09-15
Enrollment: 156
Sex: ALL
Minimum age (years): 19
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: Comparison of the clinical effectiveness and cost-effectiveness of the MIS anterolateral approach (MIS Watson Jones, G3) versus anterolateral mini or posterolateral mini approaches in primary total hip arthroplasty


Eligibility criteria: Inclusion Criteria:

No contralateral hip symptoms, no major comorbidity

Exclusion Criteria:

-

Primary outcomes:
measure: 3-months WOMAC score
timeFrame: 3 months
Secondary outcomes:
measure: Cost-effectiveness at 2-years
timeFrame: Two years
Other outcomes:
Locations:
city: Vancouver
country: Canada
facility: Vancouver General Hospital
state: British Columbia
Study officials:
affiliation: University of British Columbia
name: Nelson Greidanus, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00458861: BG9924 in Combination With Methotrexate for Participants With Active Rheumatoid Arthritis
Official title: A Phase 2b, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy, Safety, PK, and PD of BG9924 When Given in Combo With MTX to Subjects With Active RA Who Have Had an Inadequate Response to Anti-TNF
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: PHASE2
Conditions: Rheumatoid Arthritis
Keywords: Active Rheumatoid Arthritis (RA)
Lead sponsor: Biogen
Sponsor class: INDUSTRY
First posted: 2007-04-11
Enrollment: 115
Sex: ALL
Minimum age (years): 18
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This Phase 2b study is designed to evaluate the efficacy and safety of BG9924 given subcutaneously (SC) versus placebo in participants with active rheumatoid arthritis (RA) who have previously had an inadequate response to treatment with anti-tumor necrosis factor (anti-TNF) therapy.


Eligibility criteria: Key Inclusion Criteria:

* Diagnosis of rheumatoid arthritis (functional class I - III) at least 6 months prior to baseline
* Methotrexate (10 mg/week to 25 mg/week) \> 3 months prior to Day 0 (stable dose \> 4 weeks prior to Day 0)
* Must have had an inadequate response to anti-TNF therapy due to inadequate efficacy

Key Exclusion Criteria:

Medical History

* Serious local infection or systemic infection within 3 months of Day 0
* History (Hx) of recurrent infections requiring oral or parental anti-infective treatment
* Hx of tuberculosis (TB) or positive purified protein derivative (PPD) test during the screening period

Laboratory Tests

* Clinically significant lab tests at screening; or
* Positive for hepatitis C antibody or hepatitis B at screening

NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.

Primary outcomes:
measure: Evaluate efficacy of BG9924 in combination with methotrexate in RA participants who have had an inadequate response to anti-TNF therapy
timeFrame: 26 weeks
Secondary outcomes:
measure: Assess the safety and tolerability of BG9924 in this participant population.
timeFrame: 26 weeks
measure: Assess the pharmacokinetic and pharmacodynamic profile of BG9924 in this participant population.
timeFrame: 26 weeks
Other outcomes:
Locations:
city: Palo Alto
country: United States
facility: Stanford University
state: California
Study officials:
affiliation: Biogen
name: Medical Director
role: STUDY_DIRECTOR
References: